Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.2600 (-5.4%) ($5.2600 - $5.2600) on Tue. Dec. 29, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.48% (three month average) | RSI | 22 | Latest Price | $5.2600(-5.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.3% a day on average for past five trading days. | Weekly Trend | HTBX declines -7.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(36%) XBI(36%) ARKK(34%) BLOK(34%) ACES(33%) | Factors Impacting HTBX price | HTBX will decline at least -2.24% in a week (0% probabilities). VXX(-20%) VIXM(-20%) UUP(-17%) XLU(-3%) IGOV(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.24% (StdDev 4.48%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-20.47(-489.16%) | Resistance Level | $6.34 | 5 Day Moving Average | $5.63(-6.57%) | 10 Day Moving Average | $5.68(-7.39%) | 20 Day Moving Average | $6.34(-17.03%) | To recent high | -45.2% | To recent low | 0% | Market Cap | $579m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |